Bionano Genomics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Bionano Genomics (NASDAQ:BNGO) Full Year 2024 Results

Key Financial Results

• Revenue: US$30.8m (down 15% from FY 2023).
• Net loss: US$112.0m (loss narrowed by 52% from FY 2023).
• US$88.13 loss per share (improved from US$408 loss in FY 2023).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Bionano Genomics Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 6.9%. Earnings per share (EPS) missed analyst estimates by 10%.

Looking ahead, revenue is forecast to grow 3.5% p.a. on average during the next 2 years, compared to a 5.8% growth forecast for the Life Sciences industry in the US.

Performance of the American Life Sciences industry.

The company's shares are down 6.1% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with Bionano Genomics (at least 3 which are significant), and understanding these should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.